Orgenesis to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
GERMANTOWN, Md., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that Vered Caplan, Chief Executive Officer, will be presenting at the Dawson James Securities 4th Annual Small Cap Growth Conference on Tuesday, October 30th, at 12:00 PM, Eastern Time, at the Wyndham Grand Hotel in Jupiter, Florida.
If you are unable to attend, and would like to view the Company’s live webcast, please click the following link (http://wsw.com/webcast/dawson4/orgs/). The webcast will be archived for one year following the live presentation.
About Dawson James Securities
Dawson James Securities, Inc., a member of FINRA/SIPC, is a full-service investment bank headquartered in Boca Raton, FL. http://www.dawsonjames.com.
Orgenesis is a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and support services. Through its Israeli subsidiary, Orgenesis Ltd., Orgenesis is developing technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs). Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. Through its Masthercell Global subsidiary, a global contract development and manufacturing organization (CDMO), Orgenesis is able to deliver optimized process industrialization capacities to cell therapy organizations and speed up the arrival of their therapies onto the market. From technology selection to business modeling, GMP manufacturing, process development, and quality management, Masthercell’s teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. Masthercell operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin. This integrated approach supports the Company's business philosophy of bringing to market significant life-improving medical treatments. For more information, visit www.orgenesis.com.
Contact for Orgenesis:
Crescendo Communications, LLC
Released October 23, 2018